Free Trial

Fate Therapeutics (FATE) Stock Forecast & Price Target

$4.27
-0.04 (-0.93%)
(As of 07/19/2024 ET)

Fate Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 14 Wall Street analysts who have issued ratings for Fate Therapeutics in the last 12 months, the stock has a consensus rating of "Hold." Out of the 14 analysts, 1 has given a sell rating, 9 have given a hold rating, and 4 have given a buy rating for FATE.

Consensus Price Target

$6.75
58.08% Upside
High Forecast$10.00
Average Forecast$6.75
Low Forecast$5.00

According to the 14 analysts' twelve-month price targets for Fate Therapeutics, the average price target is $6.75. The highest price target for FATE is $10.00, while the lowest price target for FATE is $5.00. The average price target represents a forecasted upside of 58.08% from the current price of $4.27.

TypeCurrent Forecast
7/21/23 to 7/20/24
1 Month Ago
6/21/23 to 6/20/24
3 Months Ago
4/22/23 to 4/21/24
1 Year Ago
7/21/22 to 7/21/23
Consensus Rating
Hold
Hold
Hold
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
4 Buy rating(s)
4 Buy rating(s)
2 Buy rating(s)
4 Buy rating(s)
Hold
9 Hold rating(s)
9 Hold rating(s)
9 Hold rating(s)
14 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
2 Sell rating(s)
Consensus Price Target$6.75$6.75$6.73$13.73
Forecasted Upside58.08% Upside55.05% Upside25.38% Upside39.67% Upside
Get Fate Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter.

FATE Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

FATE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Fate Therapeutics Stock vs. The Competition

TypeFate TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.21
2.72
2.51
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside58.08% Upside3,282.90% Upside10.04% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
6/17/2024Piper Sandler
2 of 5 stars
E. Tenthoff
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Overweight$4.00 ➝ $6.00+66.20%
5/16/2024HC Wainwright
3 of 5 stars
 Lower TargetNeutral ➝ Neutral$7.00 ➝ $5.00+17.92%
5/10/2024Canaccord Genuity Group
1 of 5 stars
 Lower TargetBuy ➝ Buy$11.00 ➝ $9.00+116.35%
5/10/2024BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetMarket Perform ➝ Market Perform$7.00 ➝ $6.00+44.23%
5/6/2024Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingNeutral ➝ Neutral$7.00 ➝ $7.00+72.41%
4/11/2024Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingHold
3/28/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetUnderperform ➝ Underperform$2.00 ➝ $6.00-19.25%
2/27/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight ➝ Equal Weight$3.00 ➝ $7.00+0.72%
2/27/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$6.00 ➝ $10.00+38.89%
2/27/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMarket Perform ➝ Market Perform
11/20/2023Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$12.00 ➝ $8.00+198.51%
11/9/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetEqual Weight ➝ Equal Weight$6.00 ➝ $5.00+104.92%
9/7/2023Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingNeutral ➝ Neutral$5.00+102.43%
8/16/2023Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingHold ➝ Hold$7.00+146.48%
5/4/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$5.30 ➝ $5.00-20.38%
3/2/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$9.00 ➝ $10.00+64.20%
3/1/2023EF Hutton Acquisition Co. I
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy$10.00+58.23%
1/6/2023Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform
1/6/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$62.00 ➝ $10.00-9.09%
1/3/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral
12/15/2022The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageSell$10.00-34.94%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 05:23 PM ET.

FATE Forecast - Frequently Asked Questions

What is Fate Therapeutics' forecast for 2024?

According to the research reports of 14 Wall Street equities research analysts, the average twelve-month stock price forecast for Fate Therapeutics is $6.75, with a high forecast of $10.00 and a low forecast of $5.00.

Should I buy or sell Fate Therapeutics stock right now?

14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last twelve months. There is currently 1 sell rating, 9 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" FATE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FATE, but not buy additional shares or sell existing shares.

Does Fate Therapeutics's stock price have much upside?

According to analysts, Fate Therapeutics's stock has a predicted upside of 55.05% based on their 12-month stock forecasts.

Has Fate Therapeutics been upgraded by Wall Street analysts recently?

Over the previous 90 days, Fate Therapeutics's stock had 1 upgrade by analysts.

What analysts cover Fate Therapeutics?

Fate Therapeutics has been rated by research analysts at BMO Capital Markets, Canaccord Genuity Group, HC Wainwright, Piper Sandler, and Wedbush in the past 90 days.

Do Wall Street analysts like Fate Therapeutics more than its competitors?

Analysts like Fate Therapeutics less than other "medical" companies. The consensus rating for Fate Therapeutics is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how FATE compares to other companies.


This page (NASDAQ:FATE) was last updated on 7/20/2024 by MarketBeat.com Staff

From Our Partners